版本:
中国

BRIEF-Xenon acquires potassium channel modulator epilepsy treatment

April 26 Xenon Pharmaceuticals Inc:

* Xenon Pharmaceuticals inc says phase 2 proof-of-concept clinical trial beginning in mid-2018

* Xenon expands ion channel neurology pipeline with acquisition of new potassium channel modulator for the treatment of epilepsy

* Xenon Pharmaceuticals Inc - Xenon anticipates filing an IND, or IND equivalent, to initiate a phase 1 first-in-man clinical trial in Q4 of 2017

* Xenon Pharmaceuticals inc says anticipates filing an IND, or IND equivalent, to initiate a phase 1 first-in-man clinical trial in q4 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐